Key facts
- Decibel Bio’s last known valuation is $30.0M (Mar 2025).
- It has raised $12.0M; the latest was Early Stage VC ($12.0M) in Mar 2025.
- Notable investors include Breakthrough Energy, Future Ventures (San Francisco), Fall Line Capital, Syngenta Group Ventures, Bayer (Conglomerates) — 6 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 6 names
- ·Watchlist + deal alerts for Decibel Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Decibel Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Decibel Bio
Operator of a crop epigenetic platform intended to bring in-season epigenetic control to agriculture. The company's platform provides information regarding a foliar spray or seed treatment, at planting or in-season, and accurately predicts crop traits and agronomic outcomes more accurately than current crop models, enabling farmers to enhance nutrient uptake or boost stress tolerance of plants as weather and market conditions demand.
- Sector
- Materials and Resources
- HQ
- Berkeley, CA, United States
- Founded
- 2025
- Employees
- 13
- Website
- decibel.bio/
- Ownership
- Privately Held (backing)
Decibel Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Decibel Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Decibel Bio in its N-PORT filings yet. We sweep new filings monthly.